Genetically engineered mouse models have provided critical insights into the molecular pathways driving IPMN, demonstrating that combined GNAS and KRAS mutations induce cystic neoplasms that closely resemble human IPMN (12, 13). The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.